Literature DB >> 9000128

Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7.

G A Parker1, T Crook, M Bain, E A Sara, P J Farrell, M J Allday.   

Abstract

Epstein-Barr virus (EBV) requires six genes to efficiently immortalize human B cells. We have shown that one of these, EBNA3C, can cooperate with activated (Ha-)ras in co-transfection assays to immortalize and transform rat embryo fibroblasts (REFs). EBNA3C also augmented transformation by (Ha-)ras and a mutant p53 to a similar extent as human papilloma virus E7. As with E7 this effect was not inhibited by cotransfection with the cyclin-dependent kinase inhibitor (CDKI), a p16INK4A, which can normally activate the retinoblastoma protein (pRb) and induce growth arrest. Also like E7/ras and E1A/ras transformed cells the EBNA3C/ras transformants are very susceptible to apoptotic cell death. In vitro EBNA3C binds to pRb in a manner which is dependent on the integrity of the pocket domain; this suggests that EBNA3C, even though it lacks the LXCXE pRb binding motif found in E7 and E1A, may interact with pRb in vivo. We conclude that EBNA3C functions as an oncoprotein which directs cell cycle progression through the G1 phase restriction point when conditions might signal arrest. For the first time this demonstrates that EBV encodes a protein, functionally but not necessarily mechanistically, similar to the pRb-neutralizing nuclear antigens encoded by the 'small' DNA tumor viruses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9000128

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  61 in total

Review 1.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C.

Authors:  R Touitou; M Hickabottom; G Parker; T Crook; M J Allday
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

Review 4.  The expression and function of Epstein-Barr virus encoded latent genes.

Authors:  L S Young; C W Dawson; A G Eliopoulos
Journal:  Mol Pathol       Date:  2000-10

Review 5.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.

Authors:  S A Radkov; M Bain; P J Farrell; M West; M Rowe; M J Allday
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth.

Authors:  Seiji Maruo; Yi Wu; Taku Ito; Teru Kanda; Elliott D Kieff; Kenzo Takada
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

8.  SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen.

Authors:  Jason S Knight; Nikhil Sharma; Erle S Robertson
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription.

Authors:  Chitra Subramanian; Erle S Robertson
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1.

Authors:  Sungwook Lee; Shuhei Sakakibara; Seiji Maruo; Bo Zhao; Michael A Calderwood; Amy M Holthaus; Chiou-Yan Lai; Kenzo Takada; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.